+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Tuberculosis Testing Market by Test Type, Technology, Sample Type, End User, Distribution Channel, Application - Global Forecast 2026-2032

  • Report

  • 196 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4985927
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Tuberculosis Testing Market is projected to reach USD 2.49 Billion in 2026. It is expected to continue growing at a CAGR of 6.60%, reaching USD 3.68 Billion by 2032.

Tuberculosis testing is central to global TB control because timely diagnosis determines whether patients receive curative therapy, drug-resistance evaluation, and public health follow-up. According to the World Health Organization, an estimated 10.8 million people developed TB in 2023, and 1.25 million people died from the disease, underscoring the need for faster, more accessible diagnostic pathways.

The tuberculosis testing landscape spans tuberculin skin tests, interferon-gamma release assays, smear microscopy, culture, nucleic acid amplification tests, line probe assays, and urine lipoarabinomannan testing for eligible high-risk patients. Demand is being shaped by WHO recommendations favoring rapid molecular diagnostics as initial tests for symptomatic patients, rising drug-resistant TB surveillance needs, and expanded screening among vulnerable populations, including people living with HIV, household contacts, migrants, incarcerated populations, and individuals with diabetes or immunosuppression.

Transformative Shifts in the Tuberculosis Testing Landscape

The tuberculosis testing landscape is shifting from microscopy-led workflows toward rapid molecular testing, decentralized sample collection, and integrated drug-resistance detection. Culture remains essential for comprehensive susceptibility testing, but nucleic acid amplification tests can identify Mycobacterium tuberculosis and rifampicin resistance within hours, helping clinicians initiate appropriate treatment sooner and supporting public health teams in interrupting transmission.

Another major shift is the expansion of active case-finding beyond traditional clinics. Mobile chest X-ray, community sputum collection, digital reporting, contact investigation, and linkage-to-care platforms are improving detection in high-burden settings. These changes support national TB programs seeking to close the gap between estimated TB incidence and the number of people who are bacteriologically confirmed and notified, while also improving access for populations that face geographic, social, or economic barriers to facility-based diagnosis.

Cumulative Impact of Artificial Intelligence on TB Testing

Artificial intelligence is increasingly influencing tuberculosis testing through computer-aided detection for chest radiography, automated laboratory quality checks, workflow prioritization, and predictive outreach. WHO has stated that computer-aided detection software may be used as an alternative to human readers for TB screening and triage in people aged 15 years and older, when implemented with appropriate calibration and confirmatory testing.

AI does not replace microbiological confirmation, but it can accelerate screening, reduce reader variability, and support targeted testing in high-volume environments. The strongest use cases combine AI triage with WHO-recommended rapid molecular tests, laboratory information systems, and governance frameworks covering bias monitoring, data security, local validation, and clinical accountability. As digital chest radiography expands in community and mobile settings, AI-enabled triage is expected to remain most valuable where it shortens the pathway from symptom screening to confirmatory molecular diagnosis and treatment initiation.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific remains the largest burden environment for tuberculosis testing, led by high-incidence countries such as India, China, Indonesia, and the Philippines. The region is prioritizing rapid molecular diagnostics, private-sector notification, community screening, and drug-resistance detection to improve case finding and shorten time to treatment. Large population bases, diverse healthcare access levels, and national TB elimination strategies make Asia-Pacific a core region for molecular tuberculosis diagnostics, digital chest X-ray screening, and laboratory network strengthening.

North America and Europe are lower-incidence regions, but testing demand persists across migrants, people experiencing homelessness, correctional settings, healthcare workers, close contacts, and immunocompromised patients. In these regions, TB testing is closely linked to latent tuberculosis infection management, infection control, high-quality laboratory confirmation, and surveillance. Latin America faces urban transmission, access gaps, and uneven diagnostic capacity, creating a need for faster testing in underserved communities and stronger linkage-to-care systems. The Middle East has heterogeneous needs linked to migrant labor, border health, and national screening programs, while Africa carries a high TB and TB/HIV burden, making rapid molecular tests, urine LAM testing for eligible people with HIV, decentralized specimen referral, and integrated TB-HIV diagnostic services especially important.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are expanding molecular tuberculosis testing, digital chest X-ray screening, and community-based case finding to address persistent transmission across high-burden and lower-burden member states. The GCC emphasizes workforce screening, migrant health protocols, centralized laboratory quality, and infection prevention in highly mobile populations. The European Union supports standardized surveillance, cross-border reporting, antimicrobial resistance monitoring, and latent TB infection management among risk groups, with testing strategies shaped by low-incidence elimination goals and migration-related health priorities.

BRICS countries represent a major share of the global TB burden and include several settings with substantial drug-resistant TB challenges, making the group critical to diagnostic adoption, local production, procurement scale, and national program implementation. G7 countries influence tuberculosis testing through innovation funding, regulatory expectations, global health financing, laboratory standards, and support for high-burden countries. NATO members focus on resilient healthcare systems, military readiness, outbreak preparedness, and infectious disease surveillance that includes TB risk management for deployed personnel, mobile populations, and vulnerable communities.

Key Country Insights Across Major Tuberculosis Testing Markets

The United States and Canada maintain low TB incidence but rely on targeted testing, contact investigations, and latent TB screening among higher-risk populations, including people born in countries with higher TB burden, individuals with HIV, and immunocompromised patients. Mexico and Brazil face larger public health needs, with molecular diagnostics supporting earlier detection in urban, remote, and underserved communities. The United Kingdom, Germany, France, Italy, and Spain emphasize migrant screening, laboratory quality, contact tracing, and latent TB prevention, while Russia remains a priority country for multidrug-resistant and rifampicin-resistant TB diagnostics due to its documented drug-resistant TB burden.

China and India are pivotal due to population scale, national TB elimination strategies, and rapid test deployment across public health networks. India continues to expand molecular testing, private-sector engagement, and active case-finding initiatives, while China combines surveillance, laboratory modernization, and targeted screening in high-risk groups. Japan, Australia, and South Korea combine low-incidence surveillance with advanced laboratory networks, rigorous contact investigation, and targeted latent TB testing. Across these countries, the strongest opportunities are linked to rapid molecular testing, culture and drug-susceptibility testing, digital notification, specimen referral systems, AI-assisted radiology screening, and programs that connect diagnosis to treatment initiation without delay.

Actionable Recommendations for Tuberculosis Testing Industry Leaders

Industry leaders should align product portfolios with WHO-recommended diagnostic algorithms, especially rapid molecular tests that detect TB and key drug-resistance markers. Commercial strategies should prioritize affordability, cartridge availability, instrument uptime, biosafety, specimen logistics, and service models that work in centralized laboratories, district hospitals, mobile screening programs, and decentralized care settings.

Organizations should also invest in interoperable digital reporting, external quality assurance, sample transport, maintenance networks, and AI-enabled screening partnerships. The most defensible strategies will combine validated diagnostics with training, supply continuity, local regulatory engagement, and evidence generation that demonstrates improved case detection, faster treatment initiation, stronger drug-resistance surveillance, and reduced loss to follow-up. Partnerships with public health programs should focus on workflow integration, not only test placement, so that screening, confirmation, reporting, and treatment linkage operate as a single patient-centered pathway.

Research Methodology

This executive summary is based on a structured review of authoritative public health and scientific sources, including WHO guidance, national TB program priorities, CDC and ECDC materials, peer-reviewed diagnostic evidence, regulatory trends, and publicly available health policy information. Insights were triangulated across disease burden, testing algorithms, procurement patterns, diagnostic technology adoption, screening guidance, and laboratory implementation signals.

The methodology emphasizes verified, data-backed interpretation rather than unsupported estimates. Regional, group, and country insights were assessed through the lens of TB incidence, drug-resistant TB burden, TB/HIV co-infection, laboratory capacity, reimbursement conditions, screening policies, and the practical role of molecular diagnostics, culture, immunological testing, urine LAM testing, and AI-assisted radiology. The analysis excludes market sizing, market share, and forecasting, focusing instead on evidence-based shifts in tuberculosis testing access, clinical utility, and public health relevance.

Conclusion

Tuberculosis testing is moving toward faster, more connected, and more patient-centered diagnostic models. The combination of rapid molecular testing, targeted screening, drug-resistance detection, AI-supported triage, and digital linkage-to-care is becoming essential for national TB programs and healthcare providers aiming to reduce transmission, improve treatment outcomes, and address persistent diagnostic gaps.

For industry participants, the opportunity is not limited to test placement. Long-term value will come from reliable access, operational support, data integration, quality assurance, and evidence-based partnerships that help close diagnostic gaps in high-burden countries while maintaining surveillance strength in low-incidence markets. Organizations that support complete diagnostic pathways-from screening and confirmatory testing to reporting and treatment initiation-will be best positioned to contribute to global TB elimination priorities.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Tuberculosis Testing Market, by Test Type
7.1. Culture Test
7.1.1. Liquid Culture
7.1.2. Solid Culture
7.2. Immunological Test
7.2.1. Elisa
7.2.2. Western Blot
7.3. Molecular Test
7.3.1. Line Probe Assay
7.3.2. Pcr
7.4. Rapid Diagnostic Test
7.4.1. Chromatographic
7.4.2. Lateral Flow
8. Tuberculosis Testing Market, by Technology
8.1. Culture Based Technology
8.2. Immunodiagnostic
8.3. Lipoarabinomannan Assay
8.4. Nucleic Acid Amplification Test
9. Tuberculosis Testing Market, by Sample Type
9.1. Blood
9.2. Sputum
9.3. Urine
10. Tuberculosis Testing Market, by End User
10.1. Clinics
10.2. Hospitals
10.3. Reference Laboratory
11. Tuberculosis Testing Market, by Distribution Channel
11.1. Diagnostic Laboratory
11.2. Hospital Pharmacy
11.3. Online Pharmacy
12. Tuberculosis Testing Market, by Application
12.1. Active Tuberculosis
12.2. Latent Tuberculosis
13. Asia-Pacific Tuberculosis Testing Market
14. North America Tuberculosis Testing Market
15. Latin America Tuberculosis Testing Market
16. Europe Tuberculosis Testing Market
17. Middle East Tuberculosis Testing Market
18. Africa Tuberculosis Testing Market
19. ASEAN Tuberculosis Testing Market
20. GCC Tuberculosis Testing Market
21. European Union Tuberculosis Testing Market
22. BRICS Tuberculosis Testing Market
23. G7 Tuberculosis Testing Market
24. NATO Tuberculosis Testing Market
25. United States Tuberculosis Testing Market
26. Canada Tuberculosis Testing Market
27. Mexico Tuberculosis Testing Market
28. Brazil Tuberculosis Testing Market
29. United Kingdom Tuberculosis Testing Market
30. Germany Tuberculosis Testing Market
31. France Tuberculosis Testing Market
32. Russia Tuberculosis Testing Market
33. Italy Tuberculosis Testing Market
34. Spain Tuberculosis Testing Market
35. China Tuberculosis Testing Market
36. India Tuberculosis Testing Market
37. Japan Tuberculosis Testing Market
38. Australia Tuberculosis Testing Market
39. South Korea Tuberculosis Testing Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Abbott Laboratories
41.2. Becton, Dickinson and Company
41.3. Bio-Rad Laboratories, Inc.
41.4. Biocartis Group NV
41.5. bioMérieux SA
41.6. Bruker Corporation.
41.7. Creative Diagnostics
41.8. Danaher Corporation
41.9. DiaSorin S.p.A.
41.10. F. Hoffmann-La Roche Ltd.
41.11. Fujifilm Holdings Corporation
41.12. Hologic, Inc.
41.13. Kindstar Globalgene Technology, Inc.
41.14. Lionex GmbH
41.15. Molbio Diagnostics Limited
41.16. QIAGEN N.V.
41.17. Revvity, Inc.
41.18. SD Biosensor, Inc.
41.19. Seegene Inc.
41.20. Siemens Healthineers AG
41.21. Thermo Fisher Scientific Inc.
41.22. Zhejiang Di'an Diagnostics Technology Co., Ltd.
List of Figures
FIGURE 1. GLOBAL TUBERCULOSIS TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL TUBERCULOSIS TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL TUBERCULOSIS TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL TUBERCULOSIS TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 17. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CANADA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. MEXICO TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. GERMANY TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. ITALY TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. SPAIN TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CHINA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. INDIA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. JAPAN TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL TUBERCULOSIS TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CULTURE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CULTURE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CULTURE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LIQUID CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LIQUID CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LIQUID CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SOLID CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SOLID CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SOLID CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNOLOGICAL TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNOLOGICAL TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNOLOGICAL TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL WESTERN BLOT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL WESTERN BLOT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL WESTERN BLOT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MOLECULAR TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MOLECULAR TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MOLECULAR TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL LINE PROBE ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL LINE PROBE ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL LINE PROBE ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CHROMATOGRAPHIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CHROMATOGRAPHIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CHROMATOGRAPHIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL LATERAL FLOW MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL LATERAL FLOW MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL LATERAL FLOW MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CULTURE BASED TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CULTURE BASED TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CULTURE BASED TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IMMUNODIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IMMUNODIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL LIPOARABINOMANNAN ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL LIPOARABINOMANNAN ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL LIPOARABINOMANNAN ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL REFERENCE LABORATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL REFERENCE LABORATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL REFERENCE LABORATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL DIAGNOSTIC LABORATORY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL DIAGNOSTIC LABORATORY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL DIAGNOSTIC LABORATORY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL LATENT TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL LATENT TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL LATENT TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 103. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 105. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 130. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 131. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 132. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 133. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 134. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 135. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 136. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 147. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 150. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 152. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 153. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 154. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 155. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 156. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 157. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 158. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 163. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 164. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 165. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 166. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 167. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 168. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 169. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 171. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 172. GCC TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 173. GCC TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 174. GCC TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 175. GCC TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 176. GCC TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 177. GCC TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 178. GCC TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 179. GCC TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 180. GCC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. GCC TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. GCC TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 194. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 195. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 196. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 197. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 198. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 199. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 200. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 201. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 202. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 204. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 205. G7 TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 206. G7 TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 207. G7 TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 208. G7 TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 209. G7 TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 210. G7 TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 211. G7 TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 212. G7 TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 213. G7 TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. G7 TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 215. G7 TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 216. NATO TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 217. NATO TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 218. NATO TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 219. NATO TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 220. NATO TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 221. NATO TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 222. NATO TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 223. NATO TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 224. NATO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. NATO TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 226. NATO TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 238. CANADA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 239. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 240. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 241. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 242. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 243. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 244. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 245. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 246. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 247. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 248. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 249. MEXICO TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 250. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 251. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 252. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 253. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 254. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 255. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 256. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 257. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 258. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 259. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 260. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 261. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 262. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 263. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 264. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 265. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 266. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 267. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 268. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 269. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 270. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 271. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 272. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 282. GERMANY TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 283. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 284. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 285. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 286. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 287. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 288. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 289. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 290. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 291. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 292. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 293. FRANCE TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 294. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 295. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 296. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 297. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 298. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 299. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 300. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 301. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 302. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 303. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 304. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 305. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 306. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 307. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 308. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 309. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 310. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 311. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 312. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 313. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 314. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 315. ITALY TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 316. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 317. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 318. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 319. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 320. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 321. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 322. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 323. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 324. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 325. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 326. SPAIN TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 327. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 328. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 329. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 330. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 331. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 332. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 333. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 334. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 335. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 336. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 337. CHINA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 338. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 339. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 340. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 341. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 342. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 343. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 344. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 345. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 346. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 347. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 348. INDIA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 349. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 350. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
TABLE 351. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
TABLE 352. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
TABLE 353. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
TABLE 354. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 355. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 356. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 357. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 358. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 359. JAPAN TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 360. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Tuberculosis Testing market report include:
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis Group NV
  • bioMérieux SA
  • Bruker Corporation.
  • Creative Diagnostics
  • Danaher Corporation
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hologic, Inc.
  • Kindstar Globalgene Technology, Inc.
  • Lionex GmbH
  • Molbio Diagnostics Limited
  • QIAGEN N.V.
  • Revvity, Inc.
  • SD Biosensor, Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Zhejiang Di'an Diagnostics Technology Co., Ltd.

Table Information